Nasdaq · CIK 0001339970
ATYR aTYR PHARMA INC
Insider trading from SEC Form 4. Last filing 12 d ago. Close $0.25 on Oct 9, 2026, 0% from the 52-week low and -77% from the high.
In brief
aTYR PHARMA INC (ATYR) has 27 SEC Form 4 filings on file from 10 insiders, the latest filed on Oct 1, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
8 open-market trades have been scored at ATYR. The newest: Paul Schimmel (director) bought $50k of stock on May 27, 2026, filed May 28, 2026, scored 33 (weak). The largest of the 8 shown: Paul Schimmel (director) bought $912k on Oct 8, 2025, scored 57 (moderate). 3 insiders sold within 14 days of each other around Feb 4, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at aTYR PHARMA INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Paul Schimmel director buy | $50k 100,000 shares | +15% | +21% from low-93% from high | |
| 22Weak | Jill Marie Broadfoot Chief Financial Officer sell | $1,521 1,558 shares | -4% | +35% from low-87% from high | |
| 15Weak | Nancy Denyes General Counsel sell | $1,091 1,118 shares | -3% | +35% from low-87% from high | |
| 25Weak | Sanjay Shukla President and CEO sell | $3,655 3,745 shares | -2% | +35% from low-87% from high | |
| 57Moderate | Paul Schimmel director buy | $912k 1,000,000 shares | +242% | +45% from low-85% from high | |
| 25Weak | Jane A Gross director buy | $15k 3,750 shares | +63% | - | |
| 15Weak | Jill Marie Broadfoot Chief Financial Officer sell | $4,740 1,254 shares | -4% | - | |
| 8Weak | Nancy Denyes General Counsel sell | $3,398 899 shares | -3% | - |
Transactions
Every row filed, 38 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Brandon Yaras Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +410,000 | $0.00 | $0 | 410,000 | 12 d ago |
| May 27, 2026 | Paul Schimmel director | POpen-market purchase Common Stockindirect: See Footnote | +100,000 | $0.50 | $50k | 779,143 | May 28, 2026 |
| May 11, 2026 | Eric Benevich director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 13, 2026 |
| May 11, 2026 | Timothy Coughlin director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 13, 2026 |
| May 11, 2026 | Jane A Gross director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 13, 2026 |
| May 11, 2026 | Svetlana Lucas director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 13, 2026 |
| May 11, 2026 | Paul Schimmel director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 13, 2026 |
| May 11, 2026 | Sara Zaknoen director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 13, 2026 |
| Feb 3, 2026 | Jill Marie Broadfoot Chief Financial Officer | MOption exercise Common Stock | +3,750 | - | - | 38,854 | Feb 4, 2026 |
| Feb 3, 2026 | Nancy Denyes General Counsel | MOption exercise Common Stock | +2,687 | - | - | 34,242 | Feb 4, 2026 |
| Feb 3, 2026 | Sanjay Shukla President and CEO | MOption exercise Common Stock | +10,375 | - | - | 157,298 | Feb 4, 2026 |
| Feb 4, 2026 | Jill Marie Broadfoot Chief Financial Officer | SOpen-market sale Common Stock | -1,558 | $0.98 | $1,521 | 37,296 | Feb 4, 2026 |
| Feb 4, 2026 | Nancy Denyes General Counsel | SOpen-market sale Common Stock | -1,118 | $0.98 | $1,091 | 33,124 | Feb 4, 2026 |
| Feb 4, 2026 | Sanjay Shukla President and CEO | SOpen-market sale Common Stock | -3,745 | $0.98 | $3,655 | 153,553 | Feb 4, 2026 |
| Feb 3, 2026 | Jill Marie Broadfoot Chief Financial Officer | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 0 | Feb 4, 2026 |
| Feb 3, 2026 | Nancy Denyes General Counsel | MOption exercise Restricted Stock Unitderivative | -2,687 | $0.00 | $0 | 0 | Feb 4, 2026 |
| Feb 3, 2026 | Sanjay Shukla President and CEO | MOption exercise Restricted Stock Unitderivative | -10,375 | $0.00 | $0 | 0 | Feb 4, 2026 |
| Jan 9, 2026 | Sanjay Shukla President and CEO | AGrant or award Employee Stock Option (right to buy)derivative | +1,500,000 | $0.00 | $0 | 1,500,000 | Jan 9, 2026 |
| Jan 9, 2026 | Jill Marie Broadfoot Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +412,500 | $0.00 | $0 | 412,500 | Jan 9, 2026 |
| Jan 9, 2026 | Nancy Denyes General Counsel | AGrant or award Employee Stock Options (right to buy)derivative | +412,500 | $0.00 | $0 | 412,500 | Jan 9, 2026 |
| Oct 8, 2025 | Paul Schimmel director | POpen-market purchase Common Stockindirect: See Footnote | +682,001 | $0.90 | $612k | 1,095,024 | Oct 9, 2025 |
| Oct 9, 2025 | Paul Schimmel director | POpen-market purchase Common Stockindirect: See Footnote | +317,999 | $0.94 | $299k | 1,413,023 | Oct 9, 2025 |
| May 1, 2025 | Eric Benevich director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 2, 2025 |
| May 1, 2025 | Timothy Coughlin director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 2, 2025 |
| May 1, 2025 | Jane A Gross director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 2, 2025 |
| May 1, 2025 | Svetlana Lucas director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 2, 2025 |
| May 1, 2025 | Paul Schimmel director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 2, 2025 |
| May 1, 2025 | Sara Zaknoen director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 2, 2025 |
| Mar 17, 2025 | Jane A Gross director | POpen-market purchase Common Stock | +3,750 | $4.00 | $15k | 9,750 | Mar 17, 2025 |
| Feb 3, 2025 | Jill Marie Broadfoot Chief Financial Officer | MOption exercise Common Stock | +3,750 | - | - | 33,017 | Feb 4, 2025 |
| Feb 3, 2025 | Nancy Denyes General Counsel | MOption exercise Common Stock | +2,687 | - | - | 27,454 | Feb 4, 2025 |
| Feb 4, 2025 | Jill Marie Broadfoot Chief Financial Officer | SOpen-market sale Common Stock | -1,254 | $3.78 | $4,740 | 31,763 | Feb 4, 2025 |
| Feb 4, 2025 | Nancy Denyes General Counsel | SOpen-market sale Common Stock | -899 | $3.78 | $3,398 | 26,555 | Feb 4, 2025 |
| Feb 3, 2025 | Jill Marie Broadfoot Chief Financial Officer | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 3,750 | Feb 4, 2025 |
| Feb 3, 2025 | Nancy Denyes General Counsel | MOption exercise Restricted Stock Unitderivative | -2,687 | $0.00 | $0 | 2,687 | Feb 4, 2025 |
| Jan 8, 2025 | Jill Marie Broadfoot Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +275,000 | $0.00 | $0 | 275,000 | Jan 10, 2025 |
| Jan 8, 2025 | Nancy Denyes General Counsel | AGrant or award Employee Stock Option (right to buy)derivative | +275,000 | $0.00 | $0 | 275,000 | Jan 10, 2025 |
| Dec 10, 2024 | Eric Benevich director | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Dec 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Eric Benevichdirector, officer
- Jill Marie BroadfootChief Financial Officer
- Timothy Coughlindirector
- Nancy DenyesGeneral Counsel
- Jane A Grossdirector
- Svetlana Lucasdirector, officer
- Paul Schimmeldirector
- Sanjay ShuklaPresident and CEO
- Brandon YarasChief Financial Officer
- Sara Zaknoendirector
Questions about ATYR
Answered from the filings on this page, as of the latest one.
Are insiders buying ATYR?
No. In the last 90 days no insider at aTYR PHARMA INC bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ATYR on the open market?
Paul Schimmel (director) bought $50k of ATYR on May 27, 2026 and filed the Form 4 on May 28, 2026. InsiderTell scored 33 (weak).
How many insiders file Form 4 at aTYR PHARMA INC?
10 people have filed a Form 4 at aTYR PHARMA INC, among them Eric Benevich (director and officer), Jill Marie Broadfoot (Chief Financial Officer), Timothy Coughlin (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.